ADVFN US – Market Content Editor
-
Dollar Inches Upward as Markets Eye Upcoming Fed Meeting
On Friday, the U.S. dollar climbed modestly, recovering from a two-week low, but it remains on shaky ground as investors assess the evolving global trade environment ahead of next week’s Federal Reserve policy meeting. At 04:35 ET (08:35 GMT), the Dollar Index, which measures the dollar’s value against a basket of six currencies, edged up…
-
Positive CHMP Opinion for Gilead’s Lenacapavir in HIV Prevention
Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for lenacapavir to be used as pre-exposure prophylaxis (PrEP) against HIV. This accelerated review endorses lenacapavir to lower the risk of sexually transmitted HIV-1 infection in adults and adolescents considered at…
-
Pfizer and BioNTech Receive Positive EMA Backing for Updated COVID Vaccine
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their updated monovalent COVID-19 vaccine targeting the LP.8.1 variant. The recommendation applies to individuals aged six months and older, according to the companies’ announcement. This positive assessment from the CHMP will…
-
Dow Jones, S&P, Nasdaq, Markets React to Trade Progress, Intel Warnings, and Fed Tensions
U.S. stock futures moved slightly higher Friday, positioning Wall Street for a positive week driven by solid corporate earnings and optimism surrounding trade agreements ahead of the Trump administration’s August tariff deadline. Oil prices also rose, while Intel’s weak outlook and cost-cutting plans weighed on its shares. Trade Deals in the Spotlight Trade talks continue…
-
Gold Retreats as Risk Sentiment Grows on Trade Hopes and AI Strength
Gold prices dipped in Asian trading on Friday, continuing their pullback from recent multi-week highs as optimism around global trade developments and booming AI-sector earnings shifted investor focus away from safe-haven assets. The retreat followed a broader cooling in metal prices after strong early-week gains, though weakness in the U.S. dollar offered some support and…
-
Oil Prices Hold Gains as Traders Await Further U.S. Trade Deals and Monitor Supply Shifts
Oil prices remained stable during Friday’s Asian trading session, following notable gains on Thursday, as markets looked ahead to possible new U.S. trade agreements and supply disruptions from Russia. The price action reflects cautious optimism amid shifting geopolitical and economic developments. At 21:31 ET (01:31 GMT), Brent crude futures for September delivery ticked up 0.2%…
-
Stock Market Wrap: S&P 500, Nasdaq Notch Record Highs on Alphabet Surge
The S&P 500 and Nasdaq closed at fresh record highs Thursday, lifted by renewed optimism over trade negotiations and a strong earnings-driven rally in Alphabet. At the close of trading (4:00 p.m. ET), the Dow Jones Industrial Average dropped 316 points, or 0.7%, while the S&P 500 edged up 0.1%, and the Nasdaq Composite rose…
-
NASDAQ, S&P Hit Fresh Record Closing Highs
Wall Street turned in a mixed performance on Thursday after a strong session a day earlier, with the NASDAQ and the S&P 500 opening higher and hitting fresh record closing highs. Conversely, the Dow opened in the red and remained under water throughout the day, weighed by losses from heavyweight IBM, which may be facing…
-
Atara Biotherapeutics shares soar after FDA accepts BLA for tab-cel
Atara Biotherapeutics Inc (NASDAQ:ATRA) saw its stock jump 7% following the U.S. Food and Drug Administration’s acceptance of its Biologics License Application (BLA) for tabelecleucel (tab-cel). The BLA seeks approval for tab-cel as a standalone treatment for adults and children aged two and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have…
-
Biovie shares climb as Alzheimer’s drug shows promising age deceleration effects
Biovie Inc (NASDAQ:BIVI) shares surged 7.3% after unveiling encouraging results for its Alzheimer’s treatment bezisterim at a recent conference in Rome. The clinical-stage biotech firm reported that bezisterim significantly slowed biological aging in Alzheimer’s patients compared to placebo during its Phase 3 trial. After 30 weeks, treated patients showed age deceleration of up to 4.24…